Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

527

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease (CD)

Interventions

DRUG: Risankizumab
DRUG: Risankizumab
DRUG: Ustekinumab
DRUG: Ustekinumab

Sponsor

AbbVie